There have been some changes and additions to the Interaction Charts over the last few weeks.
On the Protease Inhibitor chart, amprenavir has been replaced by fosamprenavir. The interactions are essentially the same, apart from a few amber interactions that were due to the alcohol content of amprenavir oral solution and are not relevant for fosamprenavir.
On the NNRTI chart, etravirine (TMC 125) has been added as a column. Full details of interactions, including theoretical ones, with etravirine and other drugs are now available.
On the NRTI charts, theoretical interactions have been added for those drugs where an interaction has been studied with at least one of the NRTIs.
Finally, various new drugs have been added as rows to all the charts.
The printed versions of the charts have been updated with these changes, but due to space limitations, the new drugs (listed below) have not yet been added to the printed versions of the PI or NNRTI charts.
NEW DRUGS:
Allopurinol
Candesartan
Clavulanic acid
Codeine
Cyanocobalamine
Cytarabine
Digoxin
Dihydrocodeine
Disulfiram
Dutasteride
Entecavir
Etoposide
Ezetimibe
Fish Oils
Gliclazide
Irbesartan
Irinotecan
Posaconazole
Quetiapine
Ramipril
Spironolactone
Sulpiride
Torasemide
Varenicline
Venlafaxine
